Keyphrases
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
100%
Ponatinib
100%
Hyper-CVAD
100%
Acute Lymphoblastic Leukemia
33%
Complete Response
33%
Ph-positive
33%
Standard of Care
22%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
22%
Quantitative PCR
11%
Tyrosine Kinase Inhibitor
11%
Complete Remission
11%
Newly Diagnosed
11%
Safety Data
11%
Adverse Events
11%
Overall Survival Rate
11%
Survival Rate
11%
Intrathecal Injection
11%
Excellent Outcome
11%
Pancreatitis
11%
Philadelphia Chromosome
11%
Prednisone
11%
Dose Reduction
11%
BCR-ABL1 Tyrosine Kinase
11%
Stem Cell Transplantation
11%
Methotrexate
11%
Liver Transaminases
11%
Total Bilirubin
11%
Third Generation
11%
Myocardial Infarction
11%
Event-free Survival
11%
Hypertension
11%
New Standards
11%
Active Disease
11%
Maintenance Therapy
11%
Large Cohort
11%
Long Follow-up
11%
Cytarabine
11%
Skin Rash
11%
Central Nervous System Prophylaxis
11%
Dose Adjustment
11%
BCR-ABL1 Transcript
11%
Therapy Initiation
11%
Acceptable Safety
11%
Complete Molecular Response
11%
Hyper-CVAD Regimen
11%
Care Approach
11%
Hyper-CVAD Chemotherapy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Philadelphia 1 Chromosome
100%
Ponatinib
100%
Survival Rate
22%
Diseases
11%
Infection
11%
Vincristine
11%
Chemotherapy
11%
Protein Tyrosine Kinase Inhibitor
11%
Overall Survival
11%
Aminotransferase
11%
Rash
11%
Adverse Event
11%
Remission
11%
Intrathecal
11%
Cytarabine
11%
Prednisone
11%
Bleeding
11%
Bilirubin
11%
Methotrexate
11%
Heart Infarction
11%
Event Free Survival
11%
Pancreatitis
11%